Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Klatskin Tumor 1Gallbladder Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Advanced Biliary Tract Carcinoma 1

Interventions

Magnetic Resonance Spectroscopy 3Specimen Handling 2pembrolizumab 1olaparib 1Tegafur 1S 1 (combination) 1Observation 1Nivolumab 1Ipilimumab 1Gemcitabine 1Cisplatin 1Capecitabine 1CTLA-4 Antigen 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Bile Duct Neoplasms × Tegafur × Clear all
NCT06109779 2026-03-04

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

AstraZeneca

Phase 3 Active not recruiting
757 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡